New hope for kids with leukemia in Low-Income countries
NCT ID NCT04794296
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment plan for children with acute lymphoblastic leukemia (ALL) in low- and middle-income African countries. The plan uses stronger chemotherapy for high-risk cases and aims for an 85% remission rate. Researchers will track whether the drugs are available and if families can stick with the treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy (anthracycline, Endoxan, Methotrexate)
What this could lead to
If successful, this could provide a practical, effective treatment protocol for childhood leukemia in resource-limited settings, improving survival rates.
What could go wrong
This is an early feasibility study in low-income countries, so drug availability and adherence may be challenging. The 85% remission target is ambitious and may not be reached.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Donka 030 BP 554
RECRUITINGConakry, Guinea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Treichville à ABIDJAN
RECRUITINGAbidjan, Côte d’Ivoire
Contact Email: •••••@•••••
-
Hôpital Aristide Le Dantec, Avenue Pasteur,
RECRUITINGDakar, BP 3001, Senegal
Contact Email: •••••@•••••